Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075113 | 0.80 | ALDH1A1 (0.53) | HDAC6HDAC8NAMPT | |
| SCHEMBL30090292 | 0.79 | HDAC1 (0.59) | HDAC6HDAC8HDAC1NAMPT | |
| SCHEMBL24038582 | 0.79 | HDAC1 (0.59) | HDAC6HDAC8HDAC1NAMPT | |
| SCHEMBL28956614 | 0.78 | HDAC6 (0.50) | HDAC6HDAC8HDAC1HDAC3NAMPT | |
| SCHEMBL28205358 | 0.77 | NAMPT (0.49) | HDAC6HDAC8NAMPT | |
| SCHEMBL1027717 | 0.76 | NAMPT (0.54) | HDAC6HDAC8NAMPT | |
| SCHEMBL29168673 | 0.73 | HDAC6 (0.56) | HDAC6HDAC8HDAC1NAMPT | |
| SCHEMBL1956852 | 0.73 | ABHD6 (0.55) | HDAC6HDAC8NAMPT | |
| SCHEMBL4437450 | 0.73 | ABHD6 (0.55) | HDAC6HDAC8NAMPT | |
| SCHEMBL2124902 | 0.73 | ESR2 (0.65) | HDAC6HDAC8HDAC1HDAC3NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192677-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP11B2, CYP17A1 | HDAC6 1881/4885HDAC8 1793/4885HDAC1 802/4885 |
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | HDAC6 2352/4885HDAC8 2145/4885HDAC1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.